Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

08:57
11/23/16
11/23
08:57
11/23/16
08:57

Eli Lilly still expects to grow revenue, says Jefferies

Jefferies analyst Jeffrey Holford says that while the solanezumab Phase III trial failure is disappointing, Eli Lilly management expects to grow revenue between 2015 and 2020 while expanding margins. Further, the company is still pursuing the Alzheimer's indication though a number of other programs, Holford tells investors in a research note. The analyst previously estimated a negative solanezumab trial outcome could see the stock down $12. Shares of Lilly are currently down $10.19 to $65.80 in pre-market trading. Holford keeps a Buy rating on Lilly with a $100 price target.

  • 04

    Dec

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
11/23/16
JPMS
11/23/16
NO CHANGE
Target $85
JPMS
Overweight
JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff
JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.

TODAY'S FREE FLY STORIES

AMD

AMD

$9.45

0.77 (8.87%)

, SBUX

Starbucks

$57.44

-0.06 (-0.10%)

07:35
12/07/16
12/07
07:35
12/07/16
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AMD

AMD

$9.45

0.77 (8.87%)

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

ETE

Energy Transfer Equity

$16.56

0.49 (3.05%)

HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

JBLU

JetBlue

$21.19

0.29 (1.39%)

SWKS

Skyworks

$76.17

1.35 (1.80%)

STLD

Steel Dynamics

$38.86

0.73 (1.91%)

Z

Zillow

$37.40

2.63 (7.56%)

TEX

Terex

$31.09

1.25 (4.19%)

DRI

Darden

$77.25

0.54 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

  • 14

    Dec

  • 20

    Dec

NUS

Nu Skin

$51.56

0.05 (0.10%)

07:34
12/07/16
12/07
07:34
12/07/16
07:34
Earnings
Nu Skin sees FY17 EPS $3.10-$3.25, consensus $3.31 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

SNCR

Synchronoss

$42.59

-6.41 (-13.08%)

, IL

Intralinks

$13.12

1.85 (16.42%)

07:34
12/07/16
12/07
07:34
12/07/16
07:34
Recommendations
Synchronoss, Intralinks analyst commentary  »

Synchronoss deal has…

SNCR

Synchronoss

$42.59

-6.41 (-13.08%)

IL

Intralinks

$13.12

1.85 (16.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

NVTA

Invitae

$6.98

-0.07 (-0.99%)

07:34
12/07/16
12/07
07:34
12/07/16
07:34
Hot Stocks
Invitae announces expansion of its breast cancer STAT panel »

Invitae announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$53.72

0.16 (0.30%)

07:33
12/07/16
12/07
07:33
12/07/16
07:33
Hot Stocks
Mallinckrodt reports results from IV acetaminophen health economic analysis »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CTIX

Cellceutix

$1.14

-0.045 (-3.80%)

07:33
12/07/16
12/07
07:33
12/07/16
07:33
Hot Stocks
Cellceutix Phase 2 trial dose escalates in second cohort for Brilacidin »

Cellceutix announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$55.99

0.97 (1.76%)

, SFTBF

SoftBank

$62.00

1.93 (3.21%)

07:33
12/07/16
12/07
07:33
12/07/16
07:33
Recommendations
T-Mobile, SoftBank, Sprint, DISH, AT&T, Verizon analyst commentary  »

T-Mobile price target…

TMUS

T-Mobile

$55.99

0.97 (1.76%)

SFTBF

SoftBank

$62.00

1.93 (3.21%)

S

Sprint

$8.17

0.12 (1.49%)

DISH

DISH

$58.51

1.85 (3.27%)

T

AT&T

$39.35

0.72 (1.86%)

VZ

Verizon

$50.36

0.61 (1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 13

    Dec

  • 04

    Jan

  • 24

    Jan

NUS

Nu Skin

$51.56

0.05 (0.10%)

07:32
12/07/16
12/07
07:32
12/07/16
07:32
Hot Stocks
Nu Skin announces CEO transition plan »

Nu Skin Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CAL

Caleres

$33.80

0.28 (0.84%)

07:31
12/07/16
12/07
07:31
12/07/16
07:31
Upgrade
Caleres rating change  »

Caleres upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

, CMCSA

Comcast

$68.70

0.02 (0.03%)

07:31
12/07/16
12/07
07:31
12/07/16
07:31
Conference/Events
UBS to hold a conference »

44th Annual Global Media…

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

CMCSA

Comcast

$68.70

0.02 (0.03%)

AMT

American Tower

$100.85

-1.19 (-1.17%)

HSNI

HSN, Inc.

$35.90

-0.2 (-0.55%)

TGNA

TEGNA

$22.63

0.35 (1.57%)

CNSL

Consolidated Communications

LBTYA

Liberty Global

$29.91

0.36 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

TEVA

Teva

$35.03

-2.01 (-5.43%)

, COG

Cabot Oil & Gas

$23.57

-0.06 (-0.25%)

07:30
12/07/16
12/07
07:30
12/07/16
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TEVA

Teva

$35.03

-2.01 (-5.43%)

COG

Cabot Oil & Gas

$23.57

-0.06 (-0.25%)

FTK

Flotek

$13.11

-0.47 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 03

    Apr

07:30
12/07/16
12/07
07:30
12/07/16
07:30
General news
Treasury Market Outlook: bond yields are several ticks lower globally »

Treasury Market Outlook:…

CBS

CBS

$60.97

0.16 (0.26%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Recommendations
CBS analyst commentary  »

CBS remains a top pick at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

P

Pandora

$13.78

0.41 (3.07%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Recommendations
Pandora analyst commentary  »

Pandora Premium will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNCE

Snyder's-Lance

$36.81

0.23 (0.63%)

, LVS

Las Vegas Sands

$62.47

1.35 (2.21%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Conference/Events
Bernstein to hold a summit »

3rd Annual Consumer…

LNCE

Snyder's-Lance

$36.81

0.23 (0.63%)

LVS

Las Vegas Sands

$62.47

1.35 (2.21%)

SAP

SAP

$82.99

-0.14 (-0.17%)

TSN

Tyson Foods

$57.39

0.12 (0.21%)

TUP

Tupperware Brands

$55.46

0.24 (0.43%)

CDXC

ChromaDex

$2.39

0.05 (2.14%)

TVIA

Tvia, Inc.

$1.25

0.1 (8.70%)

HRL

Hormel Foods

$33.31

-0.48 (-1.42%)

RCL

Royal Caribbean

$81.15

0.1 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 09

    Jan

RKDA

Arcadia Biosciences

, SEED

Origin Agritech

$2.50

0.02 (0.81%)

07:28
12/07/16
12/07
07:28
12/07/16
07:28
Conference/Events
UBS to hold a conference »

2016 UBS Agriculture Day…

RKDA

Arcadia Biosciences

SEED

Origin Agritech

$2.50

0.02 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

OSIS

OSI Systems

$76.45

0.51 (0.67%)

, ZIXI

ZixCorp

$4.45

0.03 (0.68%)

07:27
12/07/16
12/07
07:27
12/07/16
07:27
Conference/Events
Imperial Capital to hold a conference »

2016 Security Investor…

OSIS

OSI Systems

$76.45

0.51 (0.67%)

ZIXI

ZixCorp

$4.45

0.03 (0.68%)

APDN

Applied DNA Sciences

$2.25

0.05 (2.27%)

ASCMA

Ascent Capital

$18.00

-0.19 (-1.04%)

BCO

Brink's

$39.95

0.9 (2.30%)

CTRL

Control4

$11.20

0.01 (0.09%)

NSSC

NAPCO Security

$8.15

0.15 (1.88%)

VRNT

Verint

$38.20

0.15 (0.39%)

INVE

Identiv

$2.58

0.11 (4.45%)

QLYS

Qualys

$32.25

-0.25 (-0.77%)

TASR

TASER

$28.19

0.11 (0.39%)

PCTI

PCTEL

$5.06

0.09 (1.81%)

RDWR

Radware

$13.64

0.07 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CGEN

Compugen

$6.10

0.1 (1.67%)

07:26
12/07/16
12/07
07:26
12/07/16
07:26
Hot Stocks
Compugen discloses cancer immunotherapy program for TIGIT »

Compugen disclosed today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$14.69

1.01 (7.38%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Conference/Events
Credit Suisse to hold a conference »

2016 Quantitative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

EW

Edwards Lifesciences

$83.22

0.73 (0.88%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ARGS

Argos Therapeutics

$4.75

0.05 (1.06%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Conference/Events
Argos Therapeutics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TCRD

THL Credit

$10.32

-0.02 (-0.19%)

, FSIC

FS Investment

$10.05

-0.05 (-0.50%)

07:24
12/07/16
12/07
07:24
12/07/16
07:24
Conference/Events
Wells Fargo to hold a forum »

2016 Middle Market…

TCRD

THL Credit

$10.32

-0.02 (-0.19%)

FSIC

FS Investment

$10.05

-0.05 (-0.50%)

BKCC

BlackRock Capital Investment

$7.41

0.08 (1.09%)

NMFC

New Mountain Finance

$14.20

-0.05 (-0.35%)

SLRC

Solar Capital

$20.67

0.14 (0.68%)

TCPC

TCP Capital

$16.95

-0.03 (-0.18%)

MAIN

Main Street

$36.37

-0.04 (-0.11%)

TSLX

TPG Specialty Lending

$18.49

0.12 (0.65%)

HTGC

Hercules Capital

$13.62

-0.12 (-0.87%)

KKR

KKR

$15.87

0.2 (1.28%)

TROW

T. Rowe Price

$76.09

0.51 (0.67%)

APO

Apollo Global

$19.28

0.03 (0.16%)

BX

Blackstone

$26.55

0.15 (0.57%)

GS

Goldman Sachs

$231.38

2.83 (1.24%)

WFC

Wells Fargo

$55.55

1.2 (2.21%)

ARCC

Ares Capital

$16.31

0.17 (1.05%)

MCC

Medley Capital

$7.63

-0.04 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 15

    Dec

WDC

Western Digital

$63.85

1.76 (2.83%)

07:24
12/07/16
12/07
07:24
12/07/16
07:24
Recommendations
Western Digital analyst commentary  »

Brean Capital ups Western…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LW

Lamb Weston

$33.82

0.17 (0.51%)

07:23
12/07/16
12/07
07:23
12/07/16
07:23
Recommendations
Lamb Weston analyst commentary  »

Lamb Weston should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FI

Frank's International

$12.51

-0.09 (-0.71%)

07:21
12/07/16
12/07
07:21
12/07/16
07:21
Syndicate
Breaking Syndicate news story on Frank's International »

Frank's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.